Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.37 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28822856 | 0.78 | CYP17A1 (0.44) | CYP19A1KDM4EKMT2ACYP17A1 | |
| SCHEMBL185527 | 0.78 | — | — | |
| SCHEMBL29331378 | 0.77 | KDM4E (0.45) | CYP19A1KDM4EKMT2ACYP17A1CYP26A1 | |
| SCHEMBL10782690 | 0.77 | KDM4E (0.42) | KDM4EKMT2ACYP26A1 | |
| SCHEMBL14317920 | 0.75 | — | — | |
| SCHEMBL408049 | 0.75 | — | — | |
| SCHEMBL10015535 | 0.75 | — | — | |
| Water SCHEMBL28065165 | 0.74 | CYP17A1 (0.46) | CYP19A1KDM4EKMT2ACYP17A1 | |
| Bromide SCHEMBL25395862 | 0.74 | CYP17A1 (0.44) | CYP19A1KDM4EKMT2ACYP17A1 | |
| Iodide SCHEMBL20816028 | 0.74 | CYP17A1 (0.44) | CYP19A1KDM4EKMT2ACYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | CYP19A1 1629/4885KDM4E 2390/4885KMT2A 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.